

Call for Abstracts

Special Session: Clinical Trials Update in Neuromuscular Diseases

The Scientific Committee of the 2027 Annual Congress of the Deutsche Gesellschaft für Muskelkranke e.V. (DGM) cordially invites investigators and research teams to submit abstracts for the **Clinical Trials Update** session. This dedicated session will provide a high-profile, independent forum for the presentation of the most recent and previously unpublished data cuts from ongoing and recently completed clinical trials in the field of neuromuscular diseases (NMD).

In keeping with the scientific mission of this congress, the session is modeled after established international formats — including the Clinical Trials session at the MDA Clinical & Scientific Conference — and is designed to accelerate the translation of emerging clinical evidence into patient care. We explicitly welcome contributions from both industry-sponsored and investigator-initiated trials.

Session Scope & Objectives

The Clinical Trials Update session aims to:

- Present the most current, previously unpublished data cuts from Phase I, II, and III clinical trials in neuromuscular diseases.
- Provide an independent, unbiased scientific platform for the exchange of emerging clinical evidence.
- Highlight advances from both sponsored trials and investigator-initiated academic research.
- Foster direct scientific dialogue between investigators, clinicians, and the broader neuromuscular community.

Submission Requirements & Eligibility Criteria

Abstracts submitted to the Clinical Trials Update session must strictly comply with the following criteria:

| | |
|---|--|
| 1 | Data currency: Abstracts must present the most recent, previously unpublished data cuts from an ongoing or recently completed clinical trial. Submission of data already published in peer-reviewed journals or presented at major international congresses prior to January 2027 is not eligible. |
| 2 | Trial phase: Only data from human clinical trials of Phase I, Phase II, or Phase III are eligible for submission. Preclinical, in vitro, or animal data are not accepted within this session. |
| 3 | No approved products: Presentations must not include efficacy or safety data from trials of products that have already received regulatory approval (EMA, FDA, or comparable national authority) for any indication at the time of abstract submission. The session is exclusively dedicated to investigational compounds and therapies. |
| 4 | No promotional content: Abstracts and presentations must be free of any commercial, promotional, or product-marketing content. The use of trade names as primary identifiers, or advertising language in slides or abstract text is strictly prohibited. International |

Nonproprietary Names (INN) or trial identifiers (e.g., ClinicalTrials.gov NCT numbers) must be used to identify investigational treatments.

Investigator-initiated trials explicitly welcome: The Scientific Committee strongly encourages the submission of data from academically driven, investigator-initiated clinical trials (IITs). Such studies are considered of equal scientific merit and will be reviewed under identical criteria.

Session Details

| | |
|------------------------|--|
| Session Title | Clinical Trials Update in Neuromuscular Diseases |
| Date & Time | Thursday, 14 January 2027 14:00–15:30 h |
| Language | English (presentations and discussion) |
| Format | Oral presentations (approx. 9 min. + 3 min. discussion per abstract) |

Abstract Submission Guidelines

Title: Maximum 150 characters (including spaces)

Abstract body: Structured format: Background, Methods, Results, Conclusions. Maximum 300 words.

Trial registration: Mandatory: provide ClinicalTrials.gov NCT number or equivalent international trial registry identifier.

Conflict of interest: All authors must disclose financial and non-financial conflicts of interest in accordance with ICMJE recommendations.

Abstract Review & Selection

All submitted abstracts will undergo blinded peer review by the Scientific Program Committee of the DGM 2027 Congress. Selection criteria include scientific novelty, methodological rigor, clinical relevance, and adherence to the eligibility requirements outlined above. Accepted abstracts will be notified by October 2026. The Scientific Committee reserves the right to reassign abstracts not meeting the session criteria to the general poster program.

Submission Portal & Deadlines

Abstract submission opens: 20th May 2026

Final submission deadline: 15th September 2026

Submission via: [Website](#)

Enquiries: abstract@conventus.de

We look forward to receiving your submissions and to welcoming you to a stimulating and scientifically rigorous session at the DGM Congress 2027 in Mannheim.